Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Asensus Surgical reports Q1 loss but eyes stability through acquisition

Asensus Surgical's Q1 2024 performance showed a significant net loss, but the potential acquisition by KARL STORZ offers financial stability. The company aims to sustain operations into Q3 2024 and beyond with available cash and additional financing. Ongoing initiatives focus on advancing surgical systems and expanding global programs.

Asensus Surgical reports Q2 losses, merger vote adjourned

Asensus Surgical faces financial struggles with a significant net loss and liquidity concerns.
The proposed merger with Karl Storz offers a potential strategic advantage but hinges on stockholder approval.
Addressing operational inefficiencies and investor engagement are critical for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™ KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™

Asensus Surgical Announces Closing of Acquisition by KARL STORZ

Asensus Surgical (ASXC) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.

Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates

Asensus Surgical, Inc. (NYSE:ASXC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Mark Klausner - IR, Westwicke Partners Anthony Fernando - President and CEO Shameze Rampertab - CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to Asensus Surgical Incorporated Second Quarter Financial and Operating Results Call. At this time, all lines are in listen-only mode.

Asensus Surgical, Inc. (ASXC) Q2 2024 Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company's Special Meeting of Stockholders, scheduled to be held on Wednesday, August 7, 2024 at 10:00 a.m. (Eastern Time), was adjourned to Tuesday, August 20, at 10:00 a.m. (Eastern Time). The Special Meeting will be held virtually.

Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned

RESEARCH TRIANGLE PARK, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), became the second advisory firm to recommend that Asensus Surgical stockholders vote “FOR” all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. (“KARL STORZ”). The vote will take place at the Company's upcoming Special Meeting of Stockholders to be held virtually at 10:00 a.m. Eastern Time on August 7, 2024.

Independent Proxy Advisory Firm ISS Recommends Asensus Surgical Stockholders Vote “FOR” the Pending Merger with KARL STORZ

RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that Asensus Surgical stockholders vote “FOR” all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. (“KARL STORZ”). The vote will take place at the Company's upcoming Special Meeting of Stockholders to be held virtually at 10:00 a.m. Eastern Time on August 7, 2024.

Glass Lewis Recommends Asensus Surgical Stockholders Vote “FOR” Proposals Relating to Proposed Merger with KARL STORZ

First Senhance® System placement at a dedicated pediatric hospital in the United States First Senhance® System placement at a dedicated pediatric hospital in the United States

Asensus Surgical Announces The Rocky Mountain Hospital for Children in Denver, Colorado to Initiate Senhance Surgery Program

RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System.

Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology

RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement to lease and utilize a Senhance® Surgical System.

Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program

Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department.

Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

Squarespace

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, ASXC on Behalf of Shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Asensus Surgical, Inc. (NYSE: ASXC) to KARL STORZ Endoscopy-America, Inc. Under the terms of the proposed transaction, shareholders of Asensus will receive $0.35 in cash for each share of Asensus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

ASENSUS SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Asensus Surgical, Inc. - ASXC

NEW YORK , June 7, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Asensus Surgical, Inc. (NYSE: ASXC ), relating to its proposed merger with KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ SE & Co. KG.

SHAREHOLDER ALERT: The M&A Class Action Investigates the Merger of Asensus Surgical, Inc. - ASXC

MILWAUKEE, June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Asensus Surgical (NYSE: ASXC) for possible breaches of fiduciary duty and other violations of law in its transaction with KARL STORZ Click here to learn how to join the investigation: https://www.ademilaw.com/case/asensus-surgical-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Shareholder Alert: Ademi LLP investigates whether Asensus Surgical, Inc. has obtained a Fair Price for its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Asensus Surgical, Inc. (NYSE American: ASXC) to KARL STORZ Endoscopy-America, Inc. for $0.35 per share in cash is fair to Asensus shareholders. Halper Sadeh encourages Asensus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation con.

ASXC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Asensus Surgical, Inc. Is Fair to Shareholders

KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company.

Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ

Asensus Surgical, Inc. (NYSE:ASXC ) Q1 2024 Earnings Conference Call May 14, 2024 2:00 PM ET Company Participants Mark Klausner - IR, Westwicke Partners Anthony Fernando - President and CEO Shameze Rampertab - CFO Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Asensus Surgical First Quarter Financial and Operating Results Call.

Asensus Surgical, Inc. (ASXC) Q1 2024 Earnings Call Transcript

Asensus Surgical (ASXC) Reports Q1 Loss, Tops Revenue Estimates

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the first quarter 2024.

Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2024

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

Second System to be Utilized by one of the Largest Private Hospital Systems in Japan RESEARCH TRIANGLE PARK, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced that Sendai Tokushukai Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program

Grab Holdings Ltd

The Metals Co

Entering the second quarter, most investors are focused on the blue-chip stocks of the world. And they should be – that's where most of the gains have been, at least for most of recent history.

News for Asensus Surgical Stock (ASXC)